All events
Politics · 2 markets

FDA moves BPC-157 to Category 1 by…?

Vol total$3K
Vol 24h$335
Liquidity$311
Resolves131d

Outcomes · most likely first

🎯
December 31, 2026
$2K vol·-1%·7d
49.5%
chance
Yes 50¢ · No 51¢
🎯
August 31, 2026
$2K vol·+6%·7d
18.8%
chance
Yes 19¢ · No 81¢

Resolution rules

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.